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Summary 
We report that a peptide from the B  chain of insulin, B(10-30), binds with high affinity to 
multiple class II proteins, including IA  b,d,k, IE  d,k, and DR.1. The ability of B(10-30) to inhibit 
the binding of other peptide antigens to class II does not correlate with its affinity for class II. 
B(10-30)  only weakly inhibits the binding of antigenic peptides.  Conversely, peptides with 
high affinity for the peptide-binding groove of various class II proteins do not inhibit B(10-30) 
binding. The rate of association of  B(10-30) with class II is unusually rapid, approaching satura- 
tion in 1-2 h  compared with 1-2 d for classical peptide antigens in the same conditions. The 
dissociation rate is also relatively rapid. The B(10-30) peptide inhibits the binding of the super- 
antigen staphylococal enterotoxin B  (SEB) to IA  k. It also inhibits SEB-mediated T  cell activa- 
tion. These observations support the conclusion that B(10-30) binds to a site outside the pep- 
tide-binding groove. Our findings indicate that short-lived peptide-class II complexes can be 
formed through interactions involving the SEB-binding site and raise the possibility that alter- 
native complexes may serve as T  cell receptor ligands. 
T 
he TCR on CD4 + T  cells recognizes peptide antigens 
associated with class II MHC glycoproteins expressed 
on the surface of APC (1). It is now clear that peptides as- 
sociate with class II molecules through a single common bind- 
ing site, the peptide-binding "groove." The first evidence for 
a single binding site came from the studies of GuiUet et al. 
(2,  3),  who  demonstrated that  the  stimulation  of antigen- 
specific T  cell hybridomas by peptide antigen was inhibited 
by unrelated peptides that shared a common capacity to be 
recognized by T  cells in association with the same class II 
molecules. The demonstration of specific binding of pep- 
tides to purified class II proteins provided a basis for the mole- 
cular analysis of class II-peptide interactions (4, 5). Buus et 
al.  (6) demonstrated that the ability of a peptide to inhibit 
binding of a specific peptide to purified class II proteins di- 
rectly correlated with the capacity of the peptide to bind to 
that particular class II protein. Thus all peptides with high 
affinity for a class II protein compete for a single common 
binding site (6). This observation was univemally confirmed in 
subsequent class II-peptide-binding studies. The high-reso- 
lution crystal structure of HLA-DR1 has recently provided 
a detailed image of this common peptide-binding site (7-9). 
Another class of antigens, the bacterial and retroviral super- 
antigens, bind to class II molecules to form complexes that 
stimulate  T  cells  sharing selected T  cell receptor V[3  do- 
mains (10,  11). The best characterized of these proteins, the 
staphylococcal enterotoxins and toxic shock syndrome toxin 
(TSST)  1 1, each bind with high affinity to a wide spectrum 
1Abbreviations used in this paper: SEB, staphylococcal  enterotoxin  B; TSST, 
toxic shock syndrome  toxin. 
of  different class II molecules (12-16). Experiments with mu- 
tant class II proteins demonstrated that amino acid substitu- 
tions differentially affect the binding ofsuperantigens and anti- 
genic peptides (17-20), The conclusion that superantigens 
bind to a site outside of  the peptide-binding groove is further 
supported by the observation that TSST-1 does not prevent 
the  binding  of antigenic  peptide  to  HLA-DR  (21).  The 
structures of  staphylococcal enterotoxin B (SEB) and TSST-1 
bound to HLA-DIL1, determined by x-ray crystallography, 
demonstrate that these superantigens interact with overlap- 
ping sites in the cxl and otl/131  domains, respectively, that 
are outside of the peptide-binding groove (9, 22). 
Here we report that a peptide from the B chain of  insulin 
binds to a variety of class II proteins with high affinity. Like 
staphylococcal superantigens, this peptide does not efficiendy 
inhibit the binding of antigenic peptides known to bind in 
the peptide-binding groove. Conversely, antigenic peptides 
do not inhibit the binding of the B chain peptide. This vio- 
lates  the general rule that unstructured peptides bind to a 
common site in class II molecules. Further evidence for an 
alternative peptide-binding site(s)  and the potential impli- 
cations of this finding are discussed. 
Materials and Methods 
Class II Purification.  IE  a and IA  d were  purified from detergent- 
solubilized A20 B lymphoma (23) membrane preparations using 
14-4-4 (anti-IE  a and -IE  k) and MKD6 (anti-IA  d) mAb immuno- 
af~nity columns (24), and IE  k and IA  k were purified from detergent- 
solubilized CH27 (25) B lymphoma membrane preparations using 
14-4-4 and 10-2-16 (anti-IA  k) mAb immunoaflLnity  columns. DILl 
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of the EBV-transformed homozygous LG2 cell line (DRBI*0101) 
using an LB3.1  (26) mAb immunoaffinity column, as previously 
described (24). 
Protein and Peptide  Antigens.  Beef insulin was purchased from 
Elanco Products Co. (Indianapolis, IN). Peptides were synthesized 
in the Emory University Microchemical Facility as described pre- 
viously (24).  SEB  was  purchased from Toxin Technology, Inc. 
(Sarasota,  FL), reconstituted, and stored as directed. Peptide se- 
quences were MAT(17-31), SGPLKAEIAQRLEDV; HEL(46-61), 
NTDGSTDYGILQINSR;  mCc(82-103),  FAGLKKANERA- 
DLIAYLKQATK;  pCc(91-104),  RADLIAYLKQATAK;  rabies 
NS(101-120),  GVQIVRQIRSGERFLKIWSQ;  p190(211-224) 
(malaria A1), YKLNFYFDLLRAKL; HIV gp41(577-595), GIK- 
QLQARILAVERYLKDQ;  NP7TPO(535-551),  LDPLIRGLL- 
ARPAKLQV;  HA(255-271),  FESTGNLIAPEYGFKIS; HA(306- 
318),  PKYVKQNTLKLAT; I(1-18), MDDQRDLISNHEQLP- 
ILG; B(1-30),  FVNQHLCGSHLVEALYLVCGERGFFYTPKA; 
B(1-22),  FVNQHLCGSHLVEALYLVCGER;  B(10-30),  HLV- 
EALYLVCGERGFFYTPKA;  B(17-30),  LVCGERGFFYTPKA; 
B(23-30),  GFFYTPKA.  MAT(17-31),  B(10-30),  mCc(82-103), 
HEL(46-61),  and SEB  were biotinylated by reaction with  excess 
N-hydroxysuccinimide--biotin in dimethyl formamide (24).  The 
peptides were precipitated in acetone and purified using HPLC, 
and SEB was dialyzed against PBS. Rabies NS(101-120), malaria A1 
peptide, NP7TPO(535-551),  HA(306-318),  and HIV gp41(577- 
595) were biotinylated through the cx-amino group before depro- 
tection and cleavage. 
Class II-Peptide-binding Assay 
Solutions.  The solutions used in this assay include the follow- 
ing: PBS =  150 mM sodium chloride, 7.5 mM sodium phosphate, 
dibasic, 2.5 mM sodium phosphate, monobasic, pH 7.2;  BBS  = 
0.125  M  borate-buffered saline, pH  8.2;  binding buffer =  100 
mM citrate/phosphate, 1 mM N-ethylmaleimide, 5 mM EDTA, 
1 mM  iodoacetamide, 1 mM  benzamidine,  1 mM  PMSF,  and 
0.2% NP-40; TTBS =  500 mM Tris, pH 7.5, and 0.1% Tween- 
20; MTB  =  5% skim milk, 1% BSA, 500 mM Tris, pH 7.5, and 
0.1% Tween-20; MTBN =  MTB +  0.5% NP-40; neutralization 
buffer  =  3.5%  skim milk, 0.7%  BSA,  335  mM  Tris,  pH  7.5, 
0.07%  sodium azide, 0.07% Tween-20,  and 0.35%  NP-40;  eu- 
ropium assay buffer =  100 mM Tris, 0.15 M  NaC1,  I% sodium 
azide, 2 I~M diethylenetriaminepentaacetic acid (Sigma Chemical 
Co., St. Louis, MO), 0.5% BSA, and 0.01% Tween-40; enhance- 
ment solution A  =  1 M  acetate, pH 3.1, 60 mM benzoyl trifluo- 
roacetone (Sigma Chemical Co.), 850 IxM yttrium oxide (Y203; 
Sigma Chemical Co.), and 5% Triton X-100; and enhancement 
solution B  =  2 M  Tris, pH 7.0, and 200 mM  1,10-phenanthro- 
line (Sigma Chemical Co.) (27, 28). 
Microtiter Assay Plate Preparation.  96-well microtiter immuno- 
assay plates  (Immulon  II; Dynatech,  Chantilly, VA)  were  pre- 
pared by initial coating with 20 btg/ml affinity-purified  goat anti- 
mouse Ig in PBS for t8 h at 4~  The plates were washed with 
PBS  and incubated with  20  Ixg/ml of class II-specific mAb in 
BBS for 18 h at 4~  or 2 h at 37~  The microtiter assay plates 
were washed with TTBS and blocked with MTB for 30 rain at 
24~  The  assay  plates  were  washed  with  TTBS,  and  50  Ixl 
MTBN was added to each well before sample addition. 
Binding Reactions.  Purified  class  II  (20-100  nM)  was  incu- 
bated  with  various  concentrations  of biotin-antigen in  30  Ixl 
binding buffer at 37~  After incubation, reactions were neutral- 
ized with an equal volume of neutralization buffer, and 50 btl was 
transferred  to prepared microtiter assay plates and incubated for 2 h 
at 4~  for capture of antigen-class II complexes. 
Detection of Antigen-Class II Complexes.  Bound biotin-antigen 
was detected using two different methods. Detection with avidin- 
alkaline phosphatase is as follows. Plates were washed with TTBS 
and  incubated  with  100  p,1  of 5  Ixg/ml avidin-alkaline phos- 
phatase for 90 rain at 24~  followed by incubation with I mg/ml 
p-nitrophenyl phosphate in  4  mM  MgC12, 0.5  M  Tris,  pH  10 
(24).  OD  was read at 405  nm with a microplate reader (model 
3550;  Bio-Rad Laboratories, Richmond,  CA).  Detection with 
europium-streptavidin was as follows. Plates were washed with 
TTBS and incubated with 100 Ixl of 100 ng/ml europium-labeled 
streptavidin (Wallac Oy, Turku, Finland) in assay buffer for 1 h at 
4~  (27).  Plates were  washed  with  TTBS,  and  100  ~1  of en- 
hancement  solution  A  was  added  per  well.  After plates  were 
shaken gently at room temperature for 10 min, 20 Ixl of enhance- 
ment solution B was added per well and the assay plates shaken at 
room temperature for 10-15 rain (28, 29). Fluorescence of each 
sample well was measured at 615  nm using a time-resolved fluo- 
rimeter (model 1230  ARCUS; LKB Wallac, Finland). The data 
points represent the OD or the mean fluorescent counts per sec- 
ond/I,000  (cps X  10 -3) of duplicate or triplicate samples.  These 
procedures allow comparison of relative OD or fluorescence within 
individual experiments but not between experiments. In satura- 
tion  experiments, free peptide concentrations were  assumed  to 
equal total peptide for Scatchard plot analysis. The results shown 
are representative of a minimum of two separate experiments. 
Culture Conditions and Lymphokine Assay.  Cultures were per- 
formed in triplicate 96-well tissue culture plates in a final volume 
of 200  ~l/well of RPMI  1640  supplemented with  10% FCS, 2 
mM glutamine, 50 IxM 2-ME,  10 Ixg/ml gentamicin, 1 mM so- 
dium pyruvate, 50 U/ml penicillin, and 50 Ixg/ml streptomycin. 
The OVA-specific, IAa-restricted T cell hybridoma 3DO-54.8 (5 
X  104/well), which recognizes SEB presented by class II MHC 
(30), was incubated with CH27 B lymphoma cells (5 ￿  104/well), 
SEB,  and peptides for 18 h.  Flat-bottom, 96-well tissue  culture 
plates were coated with various concentrations of the anti-CD3 
mAb 145-2Cll in PBS for 1.5 b at 37~  The plates were washed 
and 3DO-54.8  T  cells (5  ￿  10a/well) were added and cultured 
for 18 h in the presence or absence ofpeptide. Lymphokine pro- 
duction, reflecting T  ceU activation, was quantified by using the 
IL-2-dependent T  cell line CTLL. Culture supernatants (100 ILl) 
were transferred to flat-bottom 96-well tissue culture plates, freeze- 
thawed once, and cultured with  104 CTLL/well for 24 h. Each 
well was pulsed with 1 txCi of [3H]thynfidine during the final 10 h 
of culture. IL-2 (units per milliliter) was calculated from a stan- 
dard curve using recombinant human IL-2. 
Results 
Promiscuous Binding of an Insulin  B  Chain  Peptide to Class 
II Proteins.  Individual antigenic peptides generally bind to 
a limited number of different class II proteins, and specific- 
ity is determined by the presence of critical amino acid side 
chains appropriately spaced in the peptide sequence so that 
they can properly interact with allele-specific polymorphic 
pockets in the  class II peptide-binding site (6,  8,  31).  We 
observed that a peptide from the B  chain of insulin, B(10- 
30),  was  unusual  because  it bound  to  all class II proteins 
that  we  tested.  Biotinylated B(10-30)  was  incubated with 
purified class II proteins followed by capture with class II- 
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Figure  1.  B(10-30) binds specifically to a broad spectrum of class II 
molecules. Triplicate samples oflA  a (25 nM), IE  a (100 nM), IA  k (50 nM), 
IE  k (100 nM). and DR1 (50 nM) were each incubated with 1 I~M biotin- 
B(10-30) or 1 IxM biotin-B(10-30) and 100 IxM B(10-30) at pH 5 for 18 h 
at 37~  Peptide-class II complexes were captured with class II--specific 
mAbs, and biotin-B(10-30) binding was assayed as described in Materials 
and Methods. 
specific mAb and peptide detection with europium-strepta- 
vidin (27). B(10-30)  binds the human class II protein, DR1 
as well as IE  k, IA  k, IE  a, [A  a (Fig. 1), and IA  b (data not shown). 
The  extent  of binding  during  an  18-h  incubation  differs 
among class  II proteins with greater binding to IA than IE 
or DR  molecules.  Binding is saturable  (see below)  and in- 
hibited  by  unlabeled  B(10-30)  (Fig.  1).  No  signal  is  ob- 
tained  with  the  use  of an  irrelevant  mAb.  Thus  B(10-30) 
binds specifically to various class II proteins. 
The same core region of insulin  B  chain is required  for 
binding to different class II proteins.  Intact insulin does not 
inhibit the binding of biotin-B(10-30)  to IA  k (Fig. 2 a), IE  k 
(Fig. 2 b), or IA  a (Fig. 2 c), indicating that the protein disul- 
fide bonds must be cleaved to generate a free, unstructured 
B  chain  for class  II association.  Full-length  B  chain,  B(1- 
30), and B(10-30),  but not B(17-30),  inhibit the binding of 
biotin-B(10-30)  to IE  k, IA  k, and IA  a. The COOH-termi- 
nal  residues  of the  B  chain  are  not  required  in  the  core 
epitope since B(1-22)  inhibits  the binding of biotin-B(10- 
30). These results suggest that the minimal epitope required 
for binding to different class  II molecules is located within 
B(10-22). 
Evidence  for an Alternative Binding Site.  The relative amn- 
ity of antigenic peptides for a given class II protein can be 
determined by comparing their inhibitory capacity in com- 
petitive  binding  assays with  labeled  peptide.  As illustrated 
in Fig.  3,  a-d,  the  relative ability of a panel of peptides  to 
inhibit binding of labeled peptides to DR1 does not vary with 
the  different labeled peptides  used.  This is consistent with 
the  general  observation  that peptides  compete for a  single 
common  binding  site  in  class  II molecules  and  that  their 
ability to compete is determined only by their relative affn- 
ities. A  different result, however, is obtained with B(10-30). 
The affnity of this peptide for DR1  is ~3  logs lower than 
HA(306-318)  as measured in competition assays using four 
different  biotin-labeled  peptides,  including  HA(306-318) 
and  MAT(17-31),  which  were  defined  by specific  T  cells 
(32)  (Fig. 3, a-e). By contrast,  these peptides are unable to 
compete with biotin-B(10-30)  for binding to DR1  (Fig.  3 
e).  Low concentrations  of HA(306-318)  and MAT(17-31) 
consistendy inhibit  the binding of biotin-B(10-30)  by 25- 
50%.  However,  the  degree  of inhibition  is not further  in- 
creased  as  the  concentration  of competitor  is  increased, 
whereas  binding  is  completely  inhibited  with  increasing 
concentrations  of unlabeled B(10-30). 
Similar results are obtained with IE  k and IA  k. Low con- 
centrations of the high affnity peptide pCc(91-104)  inhibit 
the binding of 3 different biotin-peptides to [E  k (Fig. 4, a-c). 
HEL(46-61),  an immunodominant IAk-specific peptide (4), 
and B(10-30)  bind to the groove oflE k with at least 3 logs 
lower affinity than pCc(91-104).  The apparent order of af- 
finity is reversed in competition experiments using biotin- 
B(10-30)  (Fig. 4 d). HEL(46-61)  inhibits the binding ofbi- 
otin-HEL(46-61)  to  IA  k at  2-3  logs lower  concentration 
than  either  pCc(91-104)  or B(10-30)  (Fig.  5  a).  By  con- 
trast,  unlabeled  B(10-30)  is  much  more  potent  than 
HEL(46-61)  in  inhibiting  the  binding  of biotin-B(10-30) 
to this class II protein (Fig. 5 b). These results suggested that 
B(10-30)  may bind to a site in multiple class II proteins that 
is outside the peptide-binding groove. 
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Figure 2.  A common core sequence of insulin B chain determines binding to multiple class II proteins. Purified IA  k (a), IE  k (b), or IA  d (c) (100 nM 
each) were incubated in triplicate with 0.5 l~M biotin-B(10-30) for 78 h at 37~  at pH 5 with a panel of competitors (100 I~M). Biotin-peptide binding 
was measured as described in Materials and Methods. 
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Figure 3.  B(10-30) binds an alternative site in DP.I. Purified Dt(1 (75 riM) was incubated with (a) 0.05 ~M biotin-HA(306-3t8), (/7) 0.2 ~M biotin- 
MAT(17-31),  (c) 0.02 p,M biotin-HIV gp41 (577-595), (e  0 0.1 ~M biotin-NP7 TPO(535-551),  or (e) 0.1 DM biotin-B(10-30) in the presence of a panel 
of competitors at a range of concentrations. All incubations were carried out in duplicate at pH 7 for 18 h at 37~  Peptide-class II complexes were cap- 
tured with the mAb L-243, and biotin-peptide binding was measured as described in Materials and Methods. Fluorescence signals  in the absence of com- 
petitor were (a) 819.5, (b) 1163.8,  (c) 710.6, (d) 932.6, and (e) 207.6 cps ￿  10  -3. 
B(10-30) Binds Rapidly and with High A~nity to  Class II 
Proteins.  Antigenic peptides bind with remarkably slow asso- 
ciation rates to purified class II proteins, reaching saturation 
only after 24-48 h (5, 24, 33). Binding appears to involve a 
rate-limiting  peptide  exchange  reaction  that  is  associated 
with a conformational change in class II molecules  (24, 34, 
35). Once formed, the complexes are very stable,  resulting 
in  an  overall  apparent  equilibrium  dissociation  constant, 
Kd, in the range of 0.01-4  DM  (4,  5, 24,  33).  By contrast, 
superantigens  bind  with  relatively  fast  kinetics  with  half- 
times in minutes or seconds rather than hours (15, 36, 37). 
The dissociation rates are also relatively rapid (36), and re- 
ported K a values are in the range of 0.02-3 ~.M (15, 37-39). 
The kinetics of binding of B(10-30)  to class II was mea- 
sured by incubating biotin-B(10-30)  with purified class II 
proteins for various time periods. After incubations, excess 
unlabeled  B(10-30)  was  added  to  prevent  further  biotin- 
peptide binding during the capture and biotin-peptide de- 
tection steps. Biotin-B(10-30)  saturates  the alternative bind- 
ing site of IA  k within 1 h  (Fig. 6  a). A  second, slower phase 
of binding is often observed consistent with additional bind- 
ing through the peptide-binding groove. Similar kinetics are 
observed  with  IA  a,  1E  a,  IE  k,  and  DR1  (data  not  shown). 
Scatchard analysis of 18-h binding data gave an apparent Ka 
of 0.25  FtM for IA  k (Fig.  6  b). A  similar  value,  0.62  p.M, 
was obtained for DR1  (Fig. 6 c). These values probably un- 
derestimate  the binding affinity because  it  is likely  that a 
fraction  of bound peptides  dissociates  during the  immu- 
noassay, which requires 2-3 h. The apparent K a values are 
in the same range as those observed for binding of peptides 
to the peptide-binding groove, whereas the association rate 
is much faster.  Thus, it is inferred that the dissociation rate 
must also be faster than for antigens bound to the conven- 
tional peptide-binding  site,  and preliminary  experimental 
results  support this conclusion  (data not shown).  The pH 
dependence  of binding of B(10-30)  is  also  different  from 
other peptides, which generally bind to murine class II pro- 
teins much better at pH  5  than at pH 7  (24). Binding of 
B(10-30) to murine class II proteins is not enhanced at low 
pH (data not shown). 
B(10-30) Inhibits the Binding of SEB Superantigen to Puri- 
fied IA  k.  The pattern of competitive inhibition experiments 
obtained with B(10-30)  suggests two possible mechanisms. 
B(10-30)  may  bind  to  multiple  different  class  II  proteins 
through  a  common  site  that  is  distinct  from  the  peptide- 
binding groove. An alternative explanation is that this pep- 
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Figure 4.  B(10-30) binds an alterna- 
tive site in IE  k. Purified IE  k (25 riM) was 
incubated with (a) 0.5 I~M biotin-mCc 
(82-103), (b) 1.0 ~M biotin-malaria A1 
peptide,  (c)  1.0  I~M  biotin-rabies NS 
(101-120), or (d) 0.5  I~M biotin-B(10- 
30), alone or in the presence of a panel 
of competitors at a range of concentra- 
tions. All incubations  were  carried out 
in duplicate at pH 5 for  18 h at 37~ 
Peptide-class  II  complexes  were  cap- 
tured  with  14-4-4  mAb,  and  biotin- 
peptide  binding  was  measured  as 
described  in  Materials  and  Methods. 
Fluorescence  signals in the absence  of 
competitor were (a) 108.7, (b) 704.0, (c) 
187.9, and (d) 196.0 cps ￿  10 -3. 
tide preferentially binds to a different subpopulation of class 
II molecules. Staphylococcal enterotoxin superantigens bind 
to various relatively nonpolymorphic sites in the al  and [31 
domains of class II molecules outside of the peptide-bind- 
ing groove  (9,  17-22).  The  high  resolution crystal  struc- 
tures of SEB bound to DR1  provide a  detailed image of a 
superantigen binding site  (9).  We  performed  experiments 
to determine if B(10-30) binds to a site in IA  k overlapping 
with the SEB binding site determined by the crystal struc- 
ture.  The binding of biotin-SEB to  IA  k was  measured by 
immunoassay  using  the  europium  detection  system.  We 
took advantage of the fact that the IALspecific mAb 10-2-16 
does not interfere with SEB binding. The specificity of the 
SEB-binding assay is illustrated in Fig. 7  a.  A  strong signal 
was obtained when IA  k was incubated for 2  h  with 25 nM 
biotin-SEB, followed by capture with  t0-2-16 and detec- 
tion with  europium--streptavidin. No  signal was  obtained 
in controls containing either protein alone, or after capture 
with  an  inappropriate  mAb,  MKD6,  that  does  not  bind 
IA  k. SEB binding was saturable, and Scatchard analysis gave 
an apparent K a of 62 nM (Fig. 7  b). 
B(10-30) inhibited the binding ofbiotin-SEB to IA  k in a 
dose-dependent fashion  (Fig.  7  c).  No  inhibition was  ob- 
served with HEL(46-61), which binds to the peptide-bind- 
ing groove  of IA  k with high  affinity (4,  40).  Competitive 
binding experiments with  B  chain peptides  demonstrated 
that  the same core  region, B(10-22),  that was  required to 
inhibit the binding of biotin-B(10-30) (Fig. 2) also was re- 
quired to inhibit the binding of biotin-SEB to  IA  k (Fig. 7 
d). We conclude that B(10-30) binds to a site that overlaps 
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Figure  5.  B(10-30)  binds an alter- 
native site in IA  k. Purified IA  k (50 nM) 
was incubated with (a) 0.5 IJ,M biotin- 
HEL(46-61)  or  (b)  1.0  I~M  biotin- 
B(10-30)  at  pH  5  for  18 h  at  37~ 
alone or in the presence of competi- 
tors  at  a  range  of concentrations.  In 
each  experiment,  peptide-class  II 
complexes were  captured  with 10-2- 
16  mAb,  and biotin-peptide binding 
was measured as described in Materials 
and Methods.  Fluorescence signals in 
the  absence  of competitor  were  (a) 
397.5 and (b) 312.2 cps X 10 -3. 
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at pH 5 for various times at 37~  At time 0, excess unlabeled B(10-30) was added to all tubes to block additional binding ofbiotin-peptide. Peptide-class 
II complexes  were captured with 10-2-16, and biotin-peptide binding was measured as described in Materials and Methods. (b) Purified IA  k (50 nM) was 
incubated in triplicate for 18 h at 37~  at pH 5 with a range of concentrations of  biotin-B(10-30). Peptide-dass II complexes were captured with 10-2- 
16, and biotin-peptide binding was assayed as described. K  d = 0.25 I~M by Scatchard analysis. (c) Purified DR1 (75 ruM) was incubated in triplicate for 18 h 
at 37~  at pH 7 with a range of concentrations of  biotin-B(10-30). K  d = 0.62 I~M by Scatchard analysis. 
with the SEB-binding site in class II molecules and is out- 
side the peptide-binding groove. 
B(10-30)  Inhibits SEB-mediated T Cell Activation.  SEB stim- 
ulates V  138.3-expressing T  cells  such as the OVA-specific, 
IAd-restricted hybridoma 3D0-54.8 (30). Activation is dose 
dependent and requires class II-positive APC. B(10-30) in- 
hibited the response of 3DO-54.8 to SEB in the presence of 
CH27 (H-2  k) APC, whereas the control peptide,  HEL(46- 
61), did not (Fig. 8 a). This effect was only evident with limit- 
ing concentrations of SEB. Inhibition was not a result ofT cell 
toxicity since stimulation by the anti-CD3 mAb 154-2Cll 
was not altered in the presence of B(10-30) or control pep- 
tide (Fig. 8 b). 
Discussion 
In this report we demonstrate  that a peptide from the B 
chain  of insulin  binds  with  high  affinity to  class  II mole- 
cules through a site that is distinct from the peptide-bind- 
ins  groove.  Evidence  for  an  alternative  binding  site  in- 
cludes (a) promiscuous binding to multiple different class II 
molecules,  (b)  lack  of inhibition  in  competitive  peptide- 
binding experiments,  (c) unusually fast binding kinetics, and 
(d) the ability of B  chain peptides to inhibit binding of the 
superantigen  SEB  to  IA  k and  to inhibit  SEB-mediated  T 
cell activation. 
B(10-30)  was  observed  to  bind  to  at  least  six  different 
class  I[ proteins.  The suggestion that this  peptide  binds  to 
different  class  II  molecules  in  a  similar  manner  was  sup- 
ported  by  the  observation  that  the  same  core  sequence, 
B(10-22),  was required  for binding  to  each protein.  Pro- 
miscuous  class  II-binding  peptides  have  previously  been 
described (31, 41--45). However, it is very unusual for pep- 
tides to bind to both DR as well as multiple murine IA and 
IE molecules (6,  31, 46-48).  Data from the HA(306-318)/ 
DR.1  cocrystal  structure  suggest  that  a  core  sequence  of 
,-o12  amino acid residues  of the peptide intimately interact 
with the peptide-binding groove. Given the high degree of 
polymorphism  in  the  peptide-binding  pockets  of class  II 
molecules,  it  seems  unlikely  that  the  13-amino  acid  core 
sequence,  B(10-22),  would bind to multiple  different class 
II molecules through the peptide-binding groove. 
The results  of competitive peptide-binding  experiments 
provided striking contrast to the findings of previous stud- 
ies. The ability of B(10-30) to inhibit the binding of known 
antigenic peptides did not correlate with its binding affinity. 
B(10-30)  only weakly inhibited  the  binding of allele-spe- 
cific antigenic peptides to DR1,  IE  k, and IA  k. Conversely, 
high  affinity  groove-binding peptides  did  not  inhibit  the 
binding of biotin-B(10-30).  Two general mechanisms could 
account for these results.  The B  chain peptide may bind to 
a site  distinct from the  peptide-binding  groove,  or it  may 
bind  to  a  different  subpopulation  of molecules.  The  hy- 
pothesis  that  B(10-30)  binds  to  an  alternative  site  is 
strengthened by the binding kinetics data.  Peptide binding 
to class II molecules is generally very slow, reaching satura- 
tion only after 24-48 h  (5,  24,  33).  By contrast,  B(10-30) 
binding reaches a plateau in 1-2 h, and the dissociation rate 
is also much higher than that observed for other peptides. 
These kinetics are similar to those observed for superantigens 
binding to class II molecules (15, 37). The pH dependence 
of binding also differs from other peptides,  which generally 
bind to mouse class II molecules much better at pH 5 than 
pH 7. We observe very little effect ofpH  in this range on 
B(10-30)  binding.  In addition,  B(10-30)  differs from other 
high affinity peptides  because it does not form SDS-stable 
complexes with class II molecules (data not shown). 
Convincing evidence for an alternative binding site came 
from studies with the superantigen  SEB, which binds out- 
side  of the  peptide-binding  groove  (9,  17,  36).  B(10-30), 
but not HEL(46-61),  inhibited the binding of SEB to IA  k. 
The same core sequence of B chain that was required to in- 
hibit the binding of biotin-B(10-30)  to various class II pro- 
teins was also required to inhibit the binding of SEB to IA  k. 
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Purified IA  k (25 nM) was preincubated in triplicate at pH 7 for 1 h with a range of concentrations orB(10-30)  or HEL(46-61). Biotin-SEB was added to 
each sample (25 nM final concentration), and the incubation  was continued for 2 h at 37~  Biotin-SEB-class II complexes were captured with 10-2-16 
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37~  Biotin-SEB-class II complexes were captured with 10-2-16 and measured with the europium fluorescence assay. 
B(10-30) also inhibited SEB-mediated activation of Vl38.3- 
beating T  cells. SEB  exclusively interacts with the or1  do- 
main of DR1,  contacting amino acid residues from the first 
and third turns of the 13 sheet and from the external face of 
the oe helix (9). It is reasonable to assume that SEB binds to 
a similar site in IA  k (9). The assumption that SEB binds out- 
side  of the  peptide-binding groove  of IA  k is  directly sup- 
ported by the  results of mutational studies with Ao~  k  (17). 
Therefore,  we  can conclude  that  B(10-30)  binds to  a  site 
distinct from the peptide-binding groove that overlaps with 
the SEB-binding site.  High affinity binding of an unstruc- 
tured peptide to  a  site in class II molecules other than the 
peptide-binding groove has not previously been described. 
The  demonstration  of  an  alternative  binding  site  for 
B(10-30) does not rule out the possibility that this peptide may 
bind to a subpopulation of class II molecules. Although it is 
difficult to quantify the precise fraction of molecules that bind 
B(10-30),  it is  evident that  all molecules  do  not bind the 
peptide under the assay conditions used. The relatively low 
degree of binding may be in part a result ofpeptide dissocia- 
tion during the incubation periods required to separate bound 
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from free  peptide.  It is likely that B(10-30)  can bind to  a 
major fraction of the  molecules because  this peptide com- 
pletely inhibits SEB binding in a dose-dependent manner. It 
is well established that SEB binds to class II molecules con- 
taining previously bound  peptides  (9,  17,  36).  However, 
Thibodeau et al.  (49)  have  recently demonstrated that  su- 
perantigens SEB and TSST-1 bind to an overlapping site on 
different subsets of DR1  molecules. These  data  suggest that 
the identity of the peptides in the peptide-binding groove may 
influence superantigen binding (49). It is possible that groove- 
bound peptides may also influence the binding of B(10-30). 
It is unlikely that B(10-30) inhibits SEB binding because of 
homology with the class II-binding region of SEB. Pontzer 
et al.  (50)  were  able to  inhibit the binding of SEA with a 
peptide from the NH 2 terminus of SEA.  However,  <50% 
inhibition was observed with millimolar peptide concentra- 
tions (50). In our study, complete inhibition of SEB binding 
to IA  k was observed with 4 p~M B(10-30). We have not been 
able  to  identify any  significant homology  between  B(10- 
30) and sequences in SEB. 
Tampe et al. (51) have demonstrated that two peptide mol- B" 
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well) for 1.5 h alone, with 50 IMVI  B(!0-30), or with 50 p,M HEL(46-61), followed by addition of  various concentrations of SEB and further culture for 
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plates (5 ￿  104 cells/well) and cultured for 18 h alone or with 50 I-~M  peptide as indicated. Culture supernatants were collected and assayed  for IL-2 pro- 
duction as described in Materials and Methods. 
ecules can bind simultaneously to a single class II molecule. 
It has been shown that certain peptides can enhance the dis- 
sociation (52) or association (53) of unrelated peptides. This 
mechanism presumably  occurs through a  two-peptide  in- 
termediate. The site in the class II protein where the second 
peptides may bind has not been defined.  It is possible that 
they bind to the same site as B(10-30). Thus, although pep- 
tides bound in the groove may influence the binding ofsu- 
perantigens to external sites  (49), the binding ofpeptides to 
an external site may also influence the binding of peptides 
to the groove.  The fast  kinetics of binding orB(10-30)  to 
class II are reminiscent of the kinetics of formation of short- 
lived peptide-class  II complexes that may represent  inter- 
mediates in the formation of long-lived complexes (34, 54- 
56). Although these short-lived complexes have been shown 
to stabilize  empty class  II molecules at 37~  (56),  there  is 
no unequivocal evidence for their role as intermediates  in 
the formation of stable complexes. Indeed, Mason and Mc- 
Connell (57)  have demonstrated short-hved complexes be- 
tween IA  k and a peptide from myelin basic protein that do 
not lead to the formation oflong-hved complexes. Our re- 
sults with insuhn B(10-30) raise the possibility that peptides 
may interact with a site outside the peptide-binding groove 
to  form the  short-lived  complexes  described  in  previous 
studies  (34,  54-57).  The  concept that peptides  other than 
B(10-30)  can bind  to a common site  outside  the peptide- 
binding groove is supported by the observation that a tryptic 
digest of OVA inhibits biotin-B(10-30)  binding to class  II 
(data not shown). In addition, we have found that the IA  a- 
binding peptide  Myo(106-118)  inhibits  the  binding  of bi- 
otin-B(10-30)  to  multiple  class  II proteins.  The  overlap- 
ping  peptide  Myo(110-121)  was  shown  by  Beeson  and 
McConnell  (54)  to  form both  short-lived  and  long-lived 
complexes with IE  a  . 
The ability of peptides to bind an alternative site in class 
II molecules  introduces  the  possibility  that  such peptide-- 
class II complexes may be recognized by T  cells.  Although 
the  interaction  of B(10-30)  with  class  I1 shares  some fea- 
tures with superantigen binding, it is clear that this peptide 
does not stimulate large populations of T  cells like superan- 
tigens. Superantigens interact with class II molecules and T 
cell receptor V[3 domains through separate domains whose 
function depends  on the integrity of the tertiary structure. 
Unlike  superantigens,  B(10-30)  is  a  relatively  short  un- 
structured peptide with a spatial orientation that is probably 
determined by its interaction with class II. In this way it is 
similar to classical groove-binding peptide antigens. The sug- 
gestion  that  short-bred  peptide  complexes  can be  recog- 
nized by T  cells is supported by the observation that an anti- 
genic peptide from myelin basic protein binds to IA  k with a 
rapid rate of association and a 30-min dissociation half-time 
(57).  Despite  its  antigenicity,  this  peptide  does  not  form 
long-lived complexes with IA  k (57).  In preliminary studies 
we have isolated insulin B  chain-reactive,  IEk-restricted T 
cell hybridomas. It seems likely that these T  cells may rec- 
ognize B chain bound to the alternative site since B chain has 
very low affinity for the  peptide-binding  groove of IE  k as 
measured by competitive binding experiments with pCc(91- 
104). In addition, we have previously characterized a group 
of T  cells  that  recognize  a B  chain  epitope  in  an MHC- 
unrestricted  but  class  II-dependent  manner  (58).  We  are 
presently exploring the possibility that these cells recognize 
complexes formed by insulin B chain associated with an al- 
ternative binding site in class II molecules. 
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